288 related articles for article (PubMed ID: 26560171)
1. T cell immunity to dengue virus and implications for vaccine design.
Rivino L
Expert Rev Vaccines; 2016; 15(4):443-53. PubMed ID: 26560171
[TBL] [Abstract][Full Text] [Related]
2. Dengue virus vaccine development.
Yauch LE; Shresta S
Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
[TBL] [Abstract][Full Text] [Related]
3. Immune correlates for dengue vaccine development.
Srikiatkhachorn A; Yoon IK
Expert Rev Vaccines; 2016; 15(4):455-65. PubMed ID: 26560015
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
Acosta EG; Bartenschlager R
Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
[TBL] [Abstract][Full Text] [Related]
5. Dengue vaccines: challenges, development, current status and prospects.
Ghosh A; Dar L
Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
[TBL] [Abstract][Full Text] [Related]
6. Dengue vaccine development: strategies and challenges.
Ramakrishnan L; Pillai MR; Nair RR
Viral Immunol; 2015 Mar; 28(2):76-84. PubMed ID: 25494228
[TBL] [Abstract][Full Text] [Related]
7. Dengue human infection models to advance dengue vaccine development.
Larsen CP; Whitehead SS; Durbin AP
Vaccine; 2015 Dec; 33(50):7075-82. PubMed ID: 26424605
[TBL] [Abstract][Full Text] [Related]
8. Dengue vaccine: opportunities and challenges.
Hatch S; Mathew A; Rothman A
IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.
Zellweger RM; Tang WW; Eddy WE; King K; Sanchez MC; Shresta S
J Virol; 2015 Jun; 89(12):6494-505. PubMed ID: 25855749
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.
Mathew A; Townsley E; Ennis FA
Future Microbiol; 2014; 9(3):411-25. PubMed ID: 24762312
[TBL] [Abstract][Full Text] [Related]
11. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development.
Thomas SJ
Hum Vaccin Immunother; 2013 Jul; 9(7):1587-90. PubMed ID: 23466948
[TBL] [Abstract][Full Text] [Related]
12. Dengue encephalitis-associated immunopathology in the mouse model: Implications for vaccine developers and antigens inducer of cellular immune response.
Marcos E; Lazo L; Gil L; Izquierdo A; Suzarte E; Valdés I; Blanco A; Ancizar J; Alba JS; Pérez Yde L; Cobas K; Romero Y; Guillén G; Guzmán MG; Hermida L
Immunol Lett; 2016 Aug; 176():51-6. PubMed ID: 27233365
[TBL] [Abstract][Full Text] [Related]
13. Inferring Protective CD8+ T-Cell Epitopes for NS5 Protein of Four Serotypes of Dengue Virus Chinese Isolates Based on HLA-A, -B and -C Allelic Distribution: Implications for Epitope-Based Universal Vaccine Design.
Shi J; Sun J; Wu M; Hu N; Li J; Li Y; Wang H; Hu Y
PLoS One; 2015; 10(9):e0138729. PubMed ID: 26381649
[TBL] [Abstract][Full Text] [Related]
14. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
15. Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue.
Halstead SB
Lancet Infect Dis; 2017 Nov; 17(11):e378-e382. PubMed ID: 28711586
[TBL] [Abstract][Full Text] [Related]
16. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
[TBL] [Abstract][Full Text] [Related]
17. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.
Izmirly AM; Alturki SO; Alturki SO; Connors J; Haddad EK
Front Immunol; 2020; 11():1055. PubMed ID: 32655548
[TBL] [Abstract][Full Text] [Related]
18. [Research progress in the structure and function of dengue virus non-structural 1 protein].
Chen Y; Ren RW; Liu JW
Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
[TBL] [Abstract][Full Text] [Related]
19. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development.
Thomas SJ; Hombach J; Barrett A
Vaccine; 2009 Jan; 27(3):355-68. PubMed ID: 19022321
[TBL] [Abstract][Full Text] [Related]
20. New insights into the immunopathology and control of dengue virus infection.
Screaton G; Mongkolsapaya J; Yacoub S; Roberts C
Nat Rev Immunol; 2015 Dec; 15(12):745-59. PubMed ID: 26603900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
